Vinyas Innovative Technologies Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-528baeaea8ca51688ded6c77.pdf

Key Takeaways


Order Book & Revenue Visibility

Sumukh Narendra: "In the medium term? Yes, we do. Uh, we see, uh, 30 to 35% growth in the medium term going up to FY30. ... I see that we'll be in a better position in a couple of years to give a guidance post-FY30."

Supply Chain & Working Capital

Sumukh Narendra: "I don't see the supply chain challenges easing out, uh, in the next 6 to 9 months. Uh, we expect it to worsen sometime, uh, in 6 to 9 months. Uh, but right now is, uh, the situation is more looking like in, uh, the start of a semiconductor, uh, a tough period for semiconductors, uh, supplies."

US & International Expansion


Defense & Strategic Initiatives

Sumukh Narendra: "Uh, we- the growth on the defense side will continue, but the expansion is being worked on internally to ensure that, uh, the defense and aerospace segment doesn't become a large very large portion of the business."

Margins & Mix Shift

Sumukh Narendra: "We, we are working towards, uh, the target is to, uh, go into the mid, mid-teens in our EBITDA margins. Uh, that is our internal target in 3 to 4 years, uh, primarily coming from the system integration mix as well as the value mix that we are working on, and some of it coming from our exposure into our, uh, US market as well as some of the new geographies that we are working on."

Operations & AI Initiatives

Sumukh Narendra: "We have taken some initiatives internally for process improvements as well as reducing, uh, some of the mundane aspects that are there of the manufacturing process as well as the complete business process that is there. ... primarily we are looking at AI being decision support system to our manufacturing line, and, uh, that has made a significant difference over the almost the last 6 months for Vinyas."

Guidance & Commitments

CommitmentSpecificsTimeline
US facility series productionFacility complete and ready for series productionEnd of calendar year
FY27 revenue growth30–35% year-on-yearFull year FY27
H2 FY27 order inflow₹500–550 crores, primarily from export business and existing initiativesH2 FY27
H2 FY27 EBITDA margin11.5% to 12%H2 FY27
FY27 EBITDA margin11% to 12%Immediate 1 year
System integration revenue shareImprove to 45–50%Next financial year
Interest cost reductionDecrease as one-off processing fees are non-recurringBy end of March 2027
US JV FY28 revenue\$4–5 millionFY28
US JV medium-term revenueGrow to approximately \$40–45 million3–4 years
Medium-term revenue growth30–35% growthUp to FY30
Internal EBITDA margin targetMid-teens3–4 years
25,000 sq ft expansion readyDedicated system integration floor operationalEnd of FY27
SMT line expansion2 to 4 aerospace and defense linesUnderway, no completion date given
Peak revenue capacity₹2,000–2,400 croresBy end of this year

Key Metrics

MetricQ2 FY27
Revenue from operations (H1 FY27)₹290.3 cr (consolidated); no prior-year comparison available as subsidiaries were established in H2 FY26
EBITDA (H1 FY27)₹35.5 cr (consolidated)
EBITDA margin (H1 FY27)12.2% (consolidated)
Profit after tax (H1 FY27)₹14 cr (consolidated)
Expected full-year revenue growth30% to 35% YoY
Expected EBITDA margin (immediate 1 year)11% to 12%
Expected H2 FY27 EBITDA margin11.5% to 12%
Internal EBITDA margin target (3–4 years)mid-teens
Order book (as of 30 Sep 2026)₹1,430 cr, executable over 18–24 months
New orders secured (H1 FY27)₹411 cr
Expected order inflows (H2 FY27)₹500 to ₹550 cr
System integration share of business (H1 FY27)35% to 40% of revenue
Gross margin on system integration programs24% to 26%, 3–4 percentage points higher than company gross margins
US market exposure~20% of total revenue
Receivables reduction (H1 FY27)₹62 cr
Credit ratingA- stable, upgraded by CRISIL during the period
US JV facility investment (stage 1)\$1.5 million
Medium-term annual CapEx outlook₹5 to ₹6 cr
Revenue capacity by end of FY27₹2,000 to ₹2,400 cr, with 4 aerospace and defense lines at ₹500–600 cr each
US JV revenue outlook (FY28)\$4 to \$5 million, growing to \$40–\$45 million in 3–4 years
Medium-term revenue growth guidance30% to 35% through FY30